2022年10月25日

视疗法宣布通过收购扩大了管道的专利和其他资产的观点疗法。协议的财务条款没有披露。成立于2014年,观点发现和发展alpha-crystallin聚合抑制剂临床实验的非手术治疗来纠正蛋白质错误折叠的镜头。蛋白质错误折叠减少透镜弹性和清晰导致老花眼和白内障。Alpha-crystallin聚合抑制剂旨在恢复弹性和镜头清晰,可能扭转老花眼和白内障而不需要手术。“我们已经表明,眼内交付alpha-crystallin聚合抑制剂逆转年龄相关性白内障在灵长类动物,给我们信心,这种方法可能是有效的人类,”瑞德·m·Schiffman医学博士,女士MHSA,该公司的联合创始人,首席医疗官、研究和开发,在公司的新闻发布会上说。“甚至可能干预老花眼附近不仅可以恢复视力但在许多患者预防白内障的发展。观点收购提供了一个扩展库的有效药物候选高度理想的药品属性眼部交付。”Lead candidate selection is anticipated in Q1 2023. “Visus is currently conducting two phase 3 pivotal studies of its preservative-free eyedrops, Brimochol PF and Carbachol PF, for the treatment of presbyopia. The ViewPoint assets are a natural complement to this late-stage program and will enable the company to further expand its pipeline targeting the leading causes of age-related loss of vision,” said Ben Bergo, co-founder and chief executive officer of Visus. “More than a third of the world’s population have presbyopia or cataracts, and this will only increase as the population ages. A non-surgical approach to treating and possibly preventing cataracts and presbyopia could improve the quality of life of millions of people, globally, and would be a disruptive addition to the management of our patients,” said Eric D, Donnenfeld, MD, Founding Partner, Ophthalmic Consultants of New York, Clinical Professor of Ophthalmology, New York University Medical Center, and Chair of Visus’ Medical Advisory Board. Visus will share additional information during the Eyecelerator meeting at the American Academy of Ophthalmology conference in Chicago on Thursday, September 29.